Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome.
Sophanit PeppleJack ArnoldEdward M VitalAndrew C RawstronColin T PeaseShouvik DassPaul EmeryMd Yuzaiful Md YusofPublished in: ACR open rheumatology (2022)
Our data suggest that patients with pSS should be co-prescribed immunosuppressant with rituximab, and treatment should aim to achieve complete depletion. About one in six patients develop 2NDNR in repeat cycles. Humanized or type 2 anti-CD20 antibodies may improve clinical response in extra-glandular pSS.
Keyphrases
- end stage renal disease
- diffuse large b cell lymphoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- hodgkin lymphoma
- electronic health record
- machine learning
- systemic lupus erythematosus
- patient reported outcomes
- drug induced
- artificial intelligence
- deep learning
- patient reported
- nk cells